What the FDA warned about
In December 2019, the FDA warned that gabapentin and pregabalin can cause serious breathing difficulties in patients with respiratory risk factors. These include opioids or other medicines that depress the central nervous system, underlying lung conditions and older age.
Read the FDA safety communication ↗When to seek emergency help
Call 911 for slow or difficult breathing, a person who cannot be awakened, or bluish lips or skin. Do not wait for a legal consultation. This website cannot evaluate a medical emergency.
Why other medicines matter
The Neurontin prescribing information warns about respiratory depression with other central nervous system depressants, including opioids, or underlying respiratory impairment. A review needs the full medication list and clinical context, not just confirmation that gabapentin was prescribed.
Read the Neurontin prescribing information, section 5.7 ↗Records to preserve
- Emergency department, ambulance and hospital records.
- Medication names, doses and fill dates around the event.
- Existing lung disease, sleep-related breathing conditions and other diagnoses.
- Discharge summaries, toxicology reports and death records where applicable.
The presence of a warning does not by itself decide liability. The facts, product history, causation evidence and applicable law require individual review.
Breathing risk and fracture healing are different questions
The FDA communication linked above dates to December 19, 2019. It remains relevant when reviewing opioid and other sedating-medicine exposure. An October 2026 fracture-surgery study examined different outcomes in patients receiving gabapentin or pregabalin with opioids; it does not replace the FDA warning or prove the cause of an individual breathing event.
